» Authors » J Fraser Wright

J Fraser Wright

Explore the profile of J Fraser Wright including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 70
Citations 8483
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Terse P, Kells A, Noker P, Wright J, Bankiewicz K
Int J Toxicol . 2020 Nov; 40(1):4-14. PMID: 33131343
Glial cell line-derived neurotrophic factor (GDNF) is a potent neuroprotective biologic in Parkinson's disease models. Adeno-associated viral vector serotype 2 (AAV2)-human GDNF safety was assessed in rats treated with a...
12.
Wright J
Mol Ther . 2020 Jul; 28(8):1756-1758. PMID: 32710825
No abstract available.
13.
Samelson-Jones B, Finn J, Favaro P, Wright J, Arruda V
Mol Ther Methods Clin Dev . 2020 Jun; 17:1129-1138. PMID: 32490034
Adeno-associated virus (AAV) vector gene therapy is a promising treatment for a variety of genetic diseases, including hemophilia. Systemic administration of AAV vectors is associated with a cytotoxic immune response...
14.
Wright J
Mol Ther . 2020 Feb; 28(3):701-703. PMID: 32035026
No abstract available.
15.
16.
Maguire A, Russell S, Wellman J, Chung D, Yu Z, Tillman A, et al.
Ophthalmology . 2019 Aug; 126(9):1273-1285. PMID: 31443789
Purpose: To report the durability of voretigene neparvovec-rzyl (VN) adeno-associated viral vector-based gene therapy for RPE65 mutation-associated inherited retinal dystrophy (IRD), including results of a phase 1 follow-on study at...
17.
Priddy F, Lewis D, Gelderblom H, Hassanin H, Streatfield C, LaBranche C, et al.
Lancet HIV . 2019 Mar; 6(4):e230-e239. PMID: 30885692
Background: A preventive vaccine for HIV is a crucial public health need; adeno-associated virus (AAV)-mediated antibody gene delivery could be an alternative to immunisation to induce sustained expression of neutralising...
18.
Cukras C, Wiley H, Jeffrey B, Sen H, Turriff A, Zeng Y, et al.
Mol Ther . 2018 Sep; 26(9):2282-2294. PMID: 30196853
This study evaluated the safety and tolerability of ocular RS1 adeno-associated virus (AAV8-RS1) gene augmentation therapy to the retina of participants with X-linked retinoschisis (XLRS). XLRS is a monogenic trait...
19.
George L, Sullivan S, Giermasz A, Rasko J, Samelson-Jones B, Ducore J, et al.
N Engl J Med . 2017 Dec; 377(23):2215-2227. PMID: 29211678
Background: The prevention of bleeding with adequately sustained levels of clotting factor, after a single therapeutic intervention and without the need for further medical intervention, represents an important goal in...
20.
Russell S, Bennett J, Wellman J, Chung D, Yu Z, Tillman A, et al.
Lancet . 2017 Jul; 390(10097):849-860. PMID: 28712537
Background: Phase 1 studies have shown potential benefit of gene replacement in RPE65-mediated inherited retinal dystrophy. This phase 3 study assessed the efficacy and safety of voretigene neparvovec in participants...